Skip to content
Companies

Contraline

Hydrogel implant for reversible male contraception

Raised to date

$55.8M

of $115.9M offered across 1 Form D filing

Still open
$60.1M
Investors
77
Last filed
Jun 10, 2026

About

Contraline is a clinical-stage biotechnology company in Charlottesville, Virginia developing long-lasting, reversible contraceptives for men. Its lead device, ADAM, is a hydrogel implant placed in the vas deferens that blocks sperm while remaining non-hormonal and non-permanent. It is also advancing NES/T, a daily topical hormonal gel obtained through an option-to-license agreement with the Population Council. The company was founded in 2015 out of the University of Virginia and announced a $92.5 million Series B in June 2026, co-led by BVF Partners and RA Capital Management, bringing total funding to roughly $127 million.

One of the only companies to carry a long-acting, non-hormonal, reversible male contraceptive into human clinical trials, addressing a category where the only established options are condoms and vasectomy.

Funding

  • EquityFiled Jun 10, 2026Form D
    $55.8M/ $115.9M

Product

ADAM

Investigational medical device

An investigational implantable male contraceptive: an ultrasound-visible polymer is injected into the vas deferens where it forms a hydrogel acting as a semi-permeable membrane, blocking sperm while allowing fluid to pass.

  • Non-hormonal mechanism
  • Designed to last for years from a single procedure
  • Designed to be reversible

Built for

Men and couples worldwide seeking male-controlled, reversible contraception beyond currently available methods.

People on file